weiter zu epinamics.com
epinamics Company Management Development Opportunities Contact General Info 1. Dermal Applications Companies or institutions interested in the technology are invited to contact epinamics' management

epinamics GmbH
Wachtelstr. 15
D-14195 Berlin – Germany
 
Fon +4930 8312859
Fax +4930 83228521
 
E-mail info@epinamics.com
WOLFGANG KEHR (CEO)
Wolfgang Kehr, MD, PhD, is a seasoned industry professional with several decades of experience in leading positions in research, development, marketing and sales in the pharmaceutical industry both in the US and Europe. For the last 4 years in his prior position he was heading the dermatology unit of Schering AG which was spun out in 2005 as Intendis GmbH with Dr. Kehr as President and CEO. He was the driving force in the spin out process. Dr. Kehr has built up deep market knowledge and has established a valuable network in the pharmaceutical world that enables epinamics to get access to potential development and marketing partners.
Vitiligo Patch Business Strategy 2. Transdermal Applications Technological Advantages imprint & disclaimer
epinamics GmbH, Berlin
14195 Berlin Germany
 
Trade register: AG Berlin Charlottenburg, HRB 100733 B
Legal form of company: Gesellschaft mit beschränkter Haftung (limited liability company)
VAT nr. DE 248071427
 
CEO
Prof. Dr. Wolfgang Kehr
 
 
Exemption from liability
epinamics aims to maintain accurate and current information on its Web site. However, epinamics does not provide any guarantee that all information is correct, complete or up-to-date.
Links to third party Web sites are solely provided as an additional service for the user. epinamics is not responsible for the content of these sites and does not consider itself owner of said content. epinamics accepts no liability for any injury which may result from accessing a third party Web site or using the content of these sites.
 
Copyright and other property rights
The entire content of this Web site is the intellectual property of epinamics and is subject to copyright protection. The content of the site may only be used for private purposes with all copyright or other proprietary notices retained, and thereafter may not be modified, recopied, reproduced or otherwise redistributed.
 
© epinamics GmbH, Berlin, 2010. All rights reserved. All trade names on this Web site, unless stated otherwise, are the property of epinamics GmbH or its associates.
epinamics GmbH is a newly established Berlin based European pharma company with a highly attractive proprietary film forming formulation technology.
Dermal Applications
(topical therapy)

Transdermal Applications
(systemic therapy)

The company follows a “development and partnering/licensing” strategy with a number of attractive product candidates.
epinamics‘ proprietary formulation technology platform, the ‘Invisible Patch’ system, offers a broad basis for the development of specific formulation concepts for dermatological as well as transdermal applications.
Vitiligo (leukoderma) is a chronic skin disease that causes loss of pigment, resulting in irregular pale patches of skin. The worldwide prevalence is considered to be about 1%. Patients feel stigmatized and strongly suffer from the disease. No specific and approved pharmaceutical treatment is currently available. Traditional treatments by dermatologists with insufficient outcome are corticosteroid creams, UVB, PUVA and cosmetic camouflage. The ‘Invisible Patch’ technology offers a new approach to markedly improve the skin penetration of an immunmodulator with proven but so far only moderate efficacy in the treatment of Vitiligo. The invisibility and convenient application is a clear advantage of this new proprietary technology. The product allows the treatment of even prominent and irregular pale skin areas.

Advantages over Conventional Patch and Gel Technology
Oil-in-water line extensions designed for professional skin care of itching skin based on purity concept of Procuderm® Lipo products
– free from ingredients with well known allergen potential
– low number of ingredients per formulation
– excellent tolerability on damaged skin
– excellent cosmetic appearance
– effective moisturizing principle
– concept clinically tested
The patented Procuderm® lipo technology is suitable for a broad range of drugs including corticosteroids and hormones (i.e. generic development with methylprednisolone aceponate) Epicutaneous formulation containing antimicrobial substances, cell protection factor, moisturizers (emulsion and foam technology) - designed for professional skin care in prophylaxis and treatment of radiated skin - EU patent pending Emulgel formulation designed for specific acne and rosacea skin care containing antiseptic ingredients in an innovative vehicle. Medicinal composition for treatment and protection of injured, excoriated and irritated animal skin containing substances for sensorial deterrence, therapeutic substance with antiseptic and wound healing properties. - formation of a thin protective film on the wound as well as a flavour and odour barrier reventing the animal of touching or licking the wound - PCT patent pending New formulation concept with combination of bleaching agents and cell protection factor (without hydrochinone) "In vitro Liberationsstudien aus Steroidsalben" (In vitro release studies from steroid ointments),
Editio Cantor Verlag Pharm. Ind. 58, 12, 1152-1156, 1996;
Franke P et al.
"Vitamin D3 Analoque / Cyclodextrin cavitates – Manufacturing, Characterization and In vitro release from Semisolids", thesis 1998; Franke P.
patent: "Composition with Azelaic acid" [WO9925332, US000006534070B1], 1999;
Franke P., Riedl J., Günther C.
patent: "Hypoallergenic and Non-irritant Skin Care Formulations"
[EP000001214930B1], 2002;
Franke P.
patent: "Waterfree Skin Care Formulations Comprising Micronized Urea and Method of Manufacturing the same" [EP000001341515B1],
2002; Franke P., Hoffmann K.
"Film Forming Polymeric Solutions - Invisible Patch like Delivery Systems for Dermal and Transdermal Application",
32nd Annual Meeting of the Controlled Release Society, Wien, Miami Beach, USA 2005, Zurdo Schroeder I., Franke P., Schaefer U.F., Lehr C.-M.
patent: "Pharmaceutical Composition in the form of a Hydrogel for Transdermal Administration of Active Substances" [WO2004/096191A1],
2006; Franke P.
"Film Forming Polymeric Solutions as 'Invisible' Transdermal Delivery Systems for ethinylestradiol",
33rd Annual Meeting of the Controlled Release Society, Wien, Austria 2006,
Zurdo Schroeder I., Franke P., Schaefer U.F., Lehr C.-M.
"Development and characterization of film forming polymeric solutions for skin drug delivery",
Eur J Pharm Biopharm. 2007 Jan; 65(1): 111-21. Epub 2006 Jul 27, Zurdo Schroeder I., Franke P., Schaefer U.F., Lehr C.-M.
"Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs", J Control Release. 2007 Apr 2; 118(2): 196-203. Epub 2006 Dec 22, Zurdo Schroeder I., Franke P., Schaefer U.F., Lehr C.-M.
patent: "Anhydrous multiphase gel system" [WO2007014563], 2007; Franke P.
patent: "Utilization of hair polymers from the group of polyurethanes and these polymers containing pharmaceutical compositions ('Invisible patch')"
[to be published 2007], Zurdo Schroeder I., Franke P. et al
chbegriffe2); mysql_free_result($suchbegriffe3); mysql_free_result($suchbegriffe4); mysql_free_result($suchbegriffe5); ?>